Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13G

Yarrow Bioscience, Inc.

YARWNASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Nov 16, 2026Accepted Nov 16, 2026, 9:47 AM ESTFiling CIK 1566044Accession 0001193125-26-462440
Share

Structured filing — SCHEDULE 13G

primary_doc.xml

Open full document ↗

Subject company

Company
Yarrow Bioscience, Inc.
Company CIK
0001566044
Street
470 James Street
Street (continued)
Suite 007
City
New Haven
State / country code
CT
Postal code
06513

Statement details

Security class
Common Stock
Event date
09/30/2026
Rule designation
Rule 13d-1(b)

Reporting person 1

Name
Ameriprise Financial, Inc.
Citizenship / organization
DE
Reporting person type
HC
Group designation
b
Aggregate amount owned
739,538
Percent of class
8.6
Sole voting power
0
Shared voting power
724,391
Sole dispositive power
0
Shared dispositive power
739,538
Aggregate excludes certain shares
N

Reporting person 2

Name
Columbia Management Investment Advisers, LLC
Citizenship / organization
MN
Reporting person type
IA
Group designation
b
Aggregate amount owned
739,538
Percent of class
8.6
Sole voting power
0
Shared voting power
724,391
Sole dispositive power
0
Shared dispositive power
739,538
Aggregate excludes certain shares
N

Reporting person 3

Name
Columbia Small Cap Growth Fund
Citizenship / organization
MA
Reporting person type
IV
Group designation
b
Aggregate amount owned
539,115
Percent of class
6.3
Sole voting power
539,115
Shared voting power
0
Sole dispositive power
0
Shared dispositive power
539,115
Aggregate excludes certain shares
N

Item 1

Issuer

Yarrow Bioscience, Inc.

Principal executive office address

470 James Street, Suite 007, New Haven, CT 06513

Item 2

Citizenship

(a) Delaware (b) Minnesota (c) Massachusetts

Filing person

(a) Ameriprise Financial, Inc. ("AFI") (b) Columbia Management Investment Advisers, LLC ("CMIA") (c) Columbia Small Cap Growth Fund ("FUND")

Principal business or residence address

(a) 145 Ameriprise Financial Center, Minneapolis, MN 55474 (b) 290 Congress Street, Boston, MA 02210 (c) 290 Congress Street, Boston, MA 02210

Item 3

Not applicable indication

N

Type of filing person

HC

Item 4

Percent of class

The information required by Item 4(b) is set forth in Rows (5)-(9) and (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.

Amount beneficially owned

Incorporated by reference to Items (5)-(9) and (11) of the cover page pertaining to each reporting person. CMIA and AFI do not directly own any shares of Common Stock of the issuer. As the investment adviser to the Fund and various other unregistered and registered investment companies and other managed accounts, CMIA may be deemed to beneficially own the shares reported herein by the Fund. Accordingly, the shares reported herein by CMIA include those shares separately reported herein by the Fund. As the parent holding company of CMIA, AFI may be deemed to beneficially own the shares reported herein by CMIA. Accordingly, the shares reported herein by AFI include those shares separately reported herein by CMIA. Each of AFI and CMIA, and the subsidiaries identified on the attached Exhibit I, disclaims beneficial ownership of any shares reported on this Schedule.

Sole voting power

The information required by Item 4(c) is set forth in Rows (5)-(9) and (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.

Shared voting power

The information required by Item 4(c) is set forth in Rows (5)-(9) and (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.

Sole dispositive power

The information required by Item 4(c) is set forth in Rows (5)-(9) and (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.

Shared dispositive power

The information required by Item 4(c) is set forth in Rows (5)-(9) and (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.

Item 5

Not applicable indication

Y

Item 6

Not applicable indication

N

Ownership on behalf of another person

To the knowledge of AFI, CMIA and the Fund, no other persons besides AFI, CMIA and the Fund and those persons for whose shares of common stock CMIA and AFI report beneficial ownership have the right to receive or the power to direct the receipt of dividends from or the proceeds from the sale of the securities of the issuer reported herein. As of September 30, 2026, only the Fund owned more than 5% of the class of securities reported herein. Any remaining shares reported herein by CMIA are held by various other funds or accounts managed by CMIA which each have the right to receive any dividends paid by the issuer and could terminate their respective investment advisory relationship with CMIA and then subsequently direct the use of proceeds from the sale of the common stock owned by such fund or account. To CMIA's knowledge, none of these other funds or accounts own more than 5% of the outstanding shares of the issuer as of September 30, 2026.

Item 7

Not applicable indication

N

Subsidiaries

AFI: See Exhibit I

Item 8

Not applicable indication

Y

Item 9

Not applicable indication

Y

Item 10

Not applicable indication

N

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Exhibits

Exhibit Index Exhibit I Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company. Exhibit II Joint Filing Agreement

Signature comments

Contact Information Charles Chiesa VP Fund Treasurer Global Operations and Investor Services Telephone: 617-385-9593

Signature 1

Reporting person
Ameriprise Financial, Inc.
Signed
/s/ Michael G. Clarke
Title
Michael G. Clarke, Senior Vice President, North America Head of Operations & Investor Services
Date
11/16/2026

Signature 2

Reporting person
Columbia Management Investment Advisers, LLC
Signed
/s/ Michael G. Clarke
Title
Michael G. Clarke, Senior Vice President, North America Head of Operations & Investor Services
Date
11/16/2026

Signature 3

Reporting person
Columbia Small Cap Growth Fund
Signed
/s/ Michael G. Clarke
Title
Michael G. Clarke, Senior Vice President & Chief Financial Officer
Date
11/16/2026

Filed exhibits

Company context

Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company is developing YB-101, a potentially first-in-class anti-thyroid stimulating hormone receptor (“TSHR”) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both GD and TED. For more information, visit www.yarrowbioscience.com.

Current securities

Historical securities (1)

Recent company filings

  1. SCHEDULE 13G/A - filed by PERCEPTIVE ADVISORS LLC regarding Yarrow Bioscience, Inc.Nov 16, 2026
  2. SCHEDULE 13G/A - filed by Janus Henderson Group Ltd. regarding Yarrow Bioscience, Inc.Nov 16, 2026
  3. S-8 filingNov 13, 2026
  4. SCHEDULE 13G/A - filed by Nantahala Capital Management, LLC regarding Yarrow Bioscience, Inc.Nov 13, 2026
  5. 10-Q filingNov 13, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.